Expert Opinion on Biological Therapy

Papers
(The TQCC of Expert Opinion on Biological Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males116
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli63
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol55
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions54
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease52
Aflibercept biosimilars – so near, yet so far52
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?48
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases41
Antibody drug conjugates for glioblastoma: current progress towards clinical use38
Biosimilars and access to biologic therapy in immune-mediated diseases37
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)33
The endosomal-lysosomal system in ADC design and cancer therapy33
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies28
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era27
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences26
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?26
Long-acting delivery and therapies for neovascular age-related macular degeneration24
Correction24
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden23
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway23
Signaling new therapeutic opportunities: cytokines in prostate cancer22
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors21
Moving toward personalized approaches in the management of lupus nephritis20
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma20
Correction19
Correction19
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study19
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases18
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology18
Strategies for extending the half-life of biotherapeutics: successes and complications18
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment18
Unmet needs in cervical cancer – can biological therapies plug the gap?18
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies18
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)17
The nail in psoriatic arthritis: new insights into prognosis and treatment16
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?16
Management of proctitis in ulcerative colitis and the place of biological therapies16
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses16
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors16
Dynamics of biological markets with multiple biosimilar competitors in the United States16
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy16
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer15
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities15
Where do we stand with radioimmunotherapy for acute myeloid leukemia?15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective15
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease15
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives15
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies15
Biological agents targeting interleukin-13 for atopic dermatitis14
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations14
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region13
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-1913
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials13
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease13
Recent advances in delivering RNA-based therapeutics to mitochondria13
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis13
Emerging peptide-based technology for biofilm control13
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project12
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan12
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations12
An evaluation of pozelimab for the treatment of CHAPLE disease12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection12
Personalizing immunotherapy for renal cell carcinoma: how far have we come?12
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects11
Non-traditional approaches for control of antibiotic resistance11
Treating psoriasis in the elderly: biologics and small molecules11
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents11
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks11
Clinical management and innovation in fracture non-union11
Tremelimumab for the treatment of hepatocellular carcinoma11
Belimumab patient profile in Spain: evolution during the last decade and future directions11
Biosimilars in osteoporosis treatment: focus on denosumab11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective11
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)11
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside10
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target10
X-linked myotubular myopathy: an untreated treatable disease10
Sargramostim in acute radiation syndrome10
Epcoritamab in B-cell malignancies: current status and prospects10
Prostate cancer immunotherapy10
Antibody therapeutics for epithelial ovarian cancer10
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis10
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms10
Correction10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials10
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering10
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective 9
Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis9
Ravulizumab for the treatment of myasthenia gravis9
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer9
Rilonacept for the treatment of recurrent pericarditis9
Hemophilia A gene therapy: current and next-generation approaches9
Biologics in rectal cancer9
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?9
Harmonizing PD-L1 testing in metastatic triple negative breast cancer9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study9
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries9
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa8
CAR T cells for solid tumors – developments to watch in 20238
The future of cellular therapy for the treatment of renal cell carcinoma8
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives8
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto8
Belantamab mafodotin in multiple myeloma8
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study8
The future of interleukin gene therapy in head and neck cancers8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk8
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus8
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress8
0.17007803916931